<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>14(15)</volume><submitter>Shen L</submitter><journal>Cancer medicine</journal><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12304520</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>De Novo EGFR ‐ALK and EGFR ‐ROS1 Co‐Mutations in NSCLC: Clinical Characteristics, Molecular Profiling, and Treatment Outcomes From a Retrospective Analysis</pubmed_title><pmcid>PMC12304520</pmcid><pubmed_authors>Shen L</pubmed_authors><pubmed_authors>Liu K</pubmed_authors><pubmed_authors>Ma L</pubmed_authors><pubmed_authors>Liao W</pubmed_authors><pubmed_authors>Jiang Q</pubmed_authors><pubmed_authors>Gu Q</pubmed_authors><pubmed_authors>Deng H</pubmed_authors></additional><is_claimable>false</is_claimable><name>De Novo EGFR ‐ALK and EGFR ‐ROS1 Co‐Mutations in NSCLC: Clinical Characteristics, Molecular Profiling, and Treatment Outcomes From a Retrospective Analysis</name><description/><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jul</publication><modification>2026-05-28T22:16:32.019Z</modification><creation>2025-08-30T03:06:41.188Z</creation></dates><accession>S-EPMC12304520</accession><cross_references/></HashMap>